

# Investor Fact Sheet December 2025



## Company Overview

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our 16,000 global employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards has been advancing therapies to treat patients suffering from structural heart disease for more than 60 years, and this large and growing area is the company's specialty. Headquartered in Irvine, Calif., Edwards' life-saving innovations treat advanced cardiovascular disease and are sold in more than 100 countries. Edwards has manufacturing operations in North America, Europe, Singapore and Costa Rica.

## Our Strategy is Clear and Unique

**Focusing** on structural heart

**Solving** large and complex patient needs

**Pioneering** therapeutic categories with speed and agility

## Poised for Long-Term Success

- Unwavering patient-focused culture motivates and guides our global team
- Credibility and trust with clinicians, regulators, payors and patients
- Transforming patient care drives growth and secures bright future


## Quick Facts

Global Headquarters	Irvine, CA, USA
Worldwide Employees	~16,000
Website	edwards.com

## Stock Information (as of December 31, 2025)

Stock Symbol	EW
Stock Exchange	NYSE
Stock Price	\$85.25
Shares Outstanding	581.8M
Market Capitalization	\$49.6B
Total Employee Ownership	Approximately 4%

## Major Product Groups




### Transcatheter Aortic Valve Replacement

The Edwards SAPIEN family of valves continues to lead the evolution of transcatheter aortic valve replacement (TAVR), advancing care from reactive treatment of late-stage disease to a more proactive, lifetime management approach for patients with Aortic Stenosis.

### Transcatheter Mitral and Tricuspid Therapies

Edwards offers a unique and broad portfolio of transcatheter mitral and tricuspid therapies, including the PASCAL, EVOQUE and SAPIEN M3 systems, enabling a personalized, patient-centered treatment approach across the spectrum of valve disease. By combining repair and replacement solutions, Edwards equips heart teams with multiple options to tailor therapy based on each patient's individual needs.



### Surgical


Edwards has long-standing leadership and a deep commitment to advancing surgical structural heart care through continuous innovations that improves durability, expands treatment options and enhances patients' quality of life. With patients living longer and seeking better long-term outcomes, Edwards' surgical portfolio is focused on enabling lifetime management while delivering excellent clinical performance today.




Edwards

**FINANCIAL PERFORMANCE**

Non-GAAP Diluted Earnings Per Share




R&D Investment (in millions)



Q4 2025


Sales by Product Line



Percentages may not total due to rounding

Q4 2025

Sales by Geographic Location



Non-GAAP excludes certain unusual or infrequent charges


Financial performance figures are for continuing operations

**INVESTOR RELATIONS CONTACT**

(949) 250-2806  
investor\_relations@edwards.com  
Main 1-800-4-A-HEART

**Edwards' 5-Year Stock Performance as of December 31, 2025**

EW: -7% S&P 500 Healthcare Equipment: -22% S&P 500: 82%



**Technology Innovations**

**Transcatheter Aortic Valve Replacement** Edwards' leading [SAPIEN 3 Ultra RESILIA](#) system incorporates RESILIA tissue, an advanced technology that further elevates the performance of the SAPIEN 3 platform. SAPIEN is the most studied valve in the world, with more than 15 years of distinguished clinical trials involving over 10,000 patients, 10 *New England Journal of Medicine* publications and 1.2+ million patients treated around the world.

Edwards has partnered with the physician community to generate robust data that expanded access to patients regardless of risk profiles or symptom status. Data from the EARLY TAVR trial demonstrated the superiority of early TAVR intervention in severe asymptomatic aortic stenosis patients with the SAPIEN 3 platform versus clinical surveillance.

Durability remains a critical consideration as TAVR is increasingly used in patients with longer life expectancy, and the SAPIEN 3 platform is supported by the most extensive long-term randomized evidence in TAVR, including seven-year PARTNER 3 trial data and 10-year outcomes from the PARTNER II trial.

Edwards' differentiated innovation, evidence generation and indication expansion continue to drive guideline evolution, patient access and adoption of the SAPIEN platform, including pulmonary valve replacement with the [SAPIEN M3](#) valve and [Alterra](#) adaptive present.

**Transcatheter Mitral and Tricuspid Therapies** The [PASCAL Precision](#) repair platform delivers differentiated transcatheter leaflet repair for patients with mitral and tricuspid regurgitation.

The [EVOQUE](#) tricuspid replacement system expands treatment options for patients with tricuspid valve disease, providing the first and only approved transcatheter therapy for patients with limited options. In 2025, the EVOQUE system continued to generate compelling clinical evidence demonstrating hard endpoint benefits at 18 months for patients with the most severe tricuspid regurgitation.

The [SAPIEN M3](#) transcatheter mitral valve replacement system is built on the foundation of the proven SAPIEN platform and is designed specifically for mitral patients. It is the first transeptal transcatheter therapy to receive regulatory approval, receiving CE Mark in Europe and FDA approval in the U.S. in 2025 for the treatment of mitral regurgitation.

Together, these technologies reflect Edwards' commitment to personalized care, clinical evidence and continuous innovation.

**Surgical** At the center of Edwards' Surgical strategy is its differentiated RESILIA tissue technology, which represents a significant advancement in Surgical valve technology. With published clinical data showing more than 99 percent freedom from structural valve deterioration through eight years, RESILIA tissue technology has set the new standard for tissue valve durability.

The [INSPIRIS RESILIA](#) aortic valve with VFit technology meets the needs of today's patients while preserving future options. Edwards' [KONECT RESILIA](#) aortic valved conduit and [MITRIS RESILIA](#) mitral valve extend these benefits across complex aortic and mitral procedures.

Edwards believes demand for surgical therapies is growing worldwide and that its innovation strategy will continue to strengthen leadership and positive patient impact.

This document contains forward-looking statements that are based on estimates, assumptions and projections. Important factors that could cause results to differ materially from those expected by management may be found in documents filed by the company with the Securities and Exchange Commission. Some figures are not prepared in accordance with Generally Accepted Accounting Principles (GAAP). Visit [edwards.com](#) for a reconciliation of the differences between the GAAP and non-GAAP figures.

Edwards, Edwards Lifesciences, the stylized E logo, Alterra, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, Edwards SAPIEN 3 Ultra RESILIA, EVOQUE, INSPIRIS, INSPIRIS RESILIA, KONECT, KONECT RESILIA, MITRIS RESILIA, PASCAL, PASCAL Precision, RESILIA, SAPIEN, SAPIEN M3, SAPIEN X4, SAPIEN 3, SAPIEN 3 Ultra, SAPIEN 3 Ultra RESILIA, and VFit are trademarks of Edwards Lifesciences Corporation.

© 2025 Edwards Lifesciences. All rights reserved

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • [edwards.com](#)



Edwards